Literature DB >> 11447576

Modeling the effects of inhomogeneous dose distributions in normal tissues.

E D Yorke1.   

Abstract

Conformal radiation therapy frequently produces inhomogeneous dose distributions in normal tissues near the target. Most mathematical models of normal tissue complication probabilities (NTCP) are based on uniform whole or partial organ irradiation, and the model parameters are chosen to obtain agreement with clinical outcomes in these simple situations. Frequently used NTCP models and methods for including inhomogeneous dose distributions in model calculations are outlined in this report. It has been found that the model adopted may qualitatively affect prediction of complications. Limitations placed on current models by the scarcity of reliable complications data and other approaches to using the calculated dose distribution to predict NTCP are discussed. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Year:  2001        PMID: 11447576     DOI: 10.1053/srao.2001.23478

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  9 in total

1.  Use of normal tissue complication probability models in the clinic.

Authors:  Lawrence B Marks; Ellen D Yorke; Andrew Jackson; Randall K Ten Haken; Louis S Constine; Avraham Eisbruch; Søren M Bentzen; Jiho Nam; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

Review 2.  Reducing rectal injury during external beam radiotherapy for prostate cancer.

Authors:  Riccardo Valdagni; Tiziana Rancati
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

3.  A comparison of dose-response characteristics of four NTCP models using outcomes of radiation-induced optic neuropathy and retinopathy.

Authors:  Vitali Moiseenko; William Y Song; Loren K Mell; Niranjan Bhandare
Journal:  Radiat Oncol       Date:  2011-06-06       Impact factor: 3.481

4.  Radiation-Induced Liver Injury in Three-Dimensional Conformal Radiation Therapy (3D-CRT) for Postoperative or Locoregional Recurrent Gastric Cancer: Risk Factors and Dose Limitations.

Authors:  Guichao Li; Jiazhou Wang; Weigang Hu; Zhen Zhang
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

Review 5.  Modeling Radiotherapy Induced Normal Tissue Complications: An Overview beyond Phenomenological Models.

Authors:  Marco D'Andrea; Marcello Benassi; Lidia Strigari
Journal:  Comput Math Methods Med       Date:  2016-12-01       Impact factor: 2.238

Review 6.  Roadmap: proton therapy physics and biology.

Authors:  Harald Paganetti; Chris Beltran; Stefan Both; Lei Dong; Jacob Flanz; Keith Furutani; Clemens Grassberger; David R Grosshans; Antje-Christin Knopf; Johannes A Langendijk; Hakan Nystrom; Katia Parodi; Bas W Raaymakers; Christian Richter; Gabriel O Sawakuchi; Marco Schippers; Simona F Shaitelman; B K Kevin Teo; Jan Unkelbach; Patrick Wohlfahrt; Tony Lomax
Journal:  Phys Med Biol       Date:  2021-02-26       Impact factor: 4.174

7.  Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference.

Authors:  Constantinos Zamboglou; Benedikt Thomann; Khodor Koubar; Peter Bronsert; Tobias Krauss; Hans C Rischke; Ilias Sachpazidis; Vanessa Drendel; Nasr Salman; Kathrin Reichel; Cordula A Jilg; Martin Werner; Philipp T Meyer; Michael Bock; Dimos Baltas; Anca L Grosu
Journal:  Radiat Oncol       Date:  2018-05-02       Impact factor: 3.481

8.  Estimation of the risk for radiation-induced liver disease following photon- or proton-beam radiosurgery of liver metastases.

Authors:  Gracinda Mondlane; Ana Ureba; Michael Gubanski; P A Lind; Albert Siegbahn
Journal:  Radiat Oncol       Date:  2018-10-22       Impact factor: 3.481

9.  Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference.

Authors:  Simon K B Spohn; Ilias Sachpazidis; Rolf Wiehle; Benedikt Thomann; August Sigle; Peter Bronsert; Juri Ruf; Matthias Benndorf; Nils H Nicolay; Tanja Sprave; Anca L Grosu; Dimos Baltas; Constantinos Zamboglou
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.